CORRECTION article

Front. Cell. Infect. Microbiol., 03 February 2025

Sec. Clinical Microbiology

Volume 15 - 2025 | https://doi.org/10.3389/fcimb.2025.1558708

Corrigendum: Editorial: Antiviral monoclonal antibody therapies

This article is a correction to:

  1. Editorial: Antiviral Monoclonal Antibody Therapies

    1. Read original article
Catalina Florez,*Catalina Florez1,2*Denise Haslwanter*Denise Haslwanter3*Rohit K. Jangra,,*Rohit K. Jangra4,5,6*
  • 1The Henry M. Jackson Foundation, Bethesda, MD, United States
  • 2U.S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States
  • 3Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States
  • 4Department of Microbiology and Immunology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, United States
  • 5Center of Excellence for Emerging Viral Threats, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, United States
  • 6Center for Applied Immunology and Pathological Processes, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, United States

A Corrigendum on
Editorial: Antiviral monoclonal antibody therapies

By Florez C, Haslwanter D and Jangra RK (2024) Front. Cell. Infect. Microbiol. 14:1484448. doi: 10.3389/fcimb.2024.1484448

In the published article, there was an error in the Funding statement. The NIH support for Rohit K Jangra (R.K.J.) is missing. The correct Funding statement appears below.

“This work was partly supported by grants (R21AI156482 and P20GM134974 to RJ) from the National Institutes of Health, USA.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: monoclonal Abs, antiviral, SARS-CoV-2, COVID, bispecific Ab

Citation: Florez C, Haslwanter D and Jangra RK (2025) Corrigendum: Editorial: Antiviral monoclonal antibody therapies. Front. Cell. Infect. Microbiol. 15:1558708. doi: 10.3389/fcimb.2025.1558708

Received: 10 January 2025; Accepted: 13 January 2025;
Published: 03 February 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Florez, Haslwanter and Jangra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Catalina Florez, Y2F0YWxpbmEuZmxvcmV6LmN0ckBoZWFsdGgubWls; Denise Haslwanter, ZGVuaXNlLmhhc2x3YW50ZXJAZ21haWwuY29t; Rohit K. Jangra, cm9oaXQuamFuZ3JhQGxzdWhzLmVkdQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.